+

WO2000043003A1 - Utilisation therapeutique de r-warfarine en tant qu'anticoagulant - Google Patents

Utilisation therapeutique de r-warfarine en tant qu'anticoagulant Download PDF

Info

Publication number
WO2000043003A1
WO2000043003A1 PCT/GB2000/000154 GB0000154W WO0043003A1 WO 2000043003 A1 WO2000043003 A1 WO 2000043003A1 GB 0000154 W GB0000154 W GB 0000154W WO 0043003 A1 WO0043003 A1 WO 0043003A1
Authority
WO
WIPO (PCT)
Prior art keywords
warfarin
anticoagulant
cyp2c9
patients
patient
Prior art date
Application number
PCT/GB2000/000154
Other languages
English (en)
Inventor
Hazel Judith Bardsley
Ann Katherine Daly
Original Assignee
Darwin Discovery Limited
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB9901297.3A external-priority patent/GB9901297D0/en
Priority claimed from GBGB9912184.0A external-priority patent/GB9912184D0/en
Application filed by Darwin Discovery Limited filed Critical Darwin Discovery Limited
Priority to AU30648/00A priority Critical patent/AU3064800A/en
Publication of WO2000043003A1 publication Critical patent/WO2000043003A1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A61K31/366—Lactones having six-membered rings, e.g. delta-lactones
    • A61K31/37—Coumarins, e.g. psoralen

Definitions

  • Warfarin is very well known as an anticoagulant. For oral administration, it is often the agent of choice.
  • a problem associated with the use of warfarin is the need for hospitalisation and retitration of patients.
  • Warfarin is a chiral molecule.
  • the respective enantiomers are known, but are not commercially available.
  • S-Warfarin is the more potent enantiomer.
  • R- and S-warfarin have different pharmacokinetic and anticoagulant properties. Their different metabolisms mean that their drug interaction characteristics are different.
  • the present invention is based at least in part on the discovery of an association of polymorphisms in the cytochrome P450 CYP2C9 with warfarin dose requirements.
  • CYP2C9 genotyping has identified a sub-group of patients who have difficulty at induction of warfarin therapy, and are potentially at a higher risk of bleeding complications.
  • the present invention is based also on the realisation that patients expressing certain allelic variants ofCYP2C9 (e.g. CYP2C9* l/*2;* l/*3;*2/*3;*2/*2) are particularly susceptible to problems that are apparently associated with the administration of S- warfarin.
  • R-warfarin can be given to patients without the risk of incurring such problems. Accordingly, R-warfarin is inherently a safer anticoagulant. For example, patients requiring an unusually high dose of warfarin for effective anticoagulant therapy can use R-warfarin more safely.
  • such patients and also those who are sensitive to, or cannot be stabilised on, racemic warfarin, are given R-warfarin as an anticoagulant.
  • a low dosage of the active component (or at least a lower dosage than would be expected given its lower potency) can be used effectively.
  • S-warfarin can be used to detect the presence of the allelic variants of CYP2C9 in a sample taken from a human.
  • Patients suitable for therapy according to the present invention can be readily identified. Firstly, many people who cannot be stabilised on racemic warfarin are already known, and may have been offered alternative treatment. Others can be readily identified by the same means. Secondly, individuals exhibiting the indicated CYP2C9 variants can be identified by a simple diagnostic test; see the discussion of genotyping below. Alternatively, S-warfarin can be used for this purpose. Individuals for whom the invention is particularly suitable include those taking non- steroidal anti-inflammatory drugs or antibiotics, as drug interactions with warfarin may be avoided. Further, the invention may be particularly suitable for the treatment of individuals suffering from cardiovascular disease, and also the old, e.g. 50, 60, 70 or older, and/or obese. These are merely examples of patient populations that may benefit from the administration of R-warfarin. It may be noted that patients requiring warfarin therapy will typically be taking other medicaments.
  • R-warfarin is suitably administered to patents also undergoing treatment with another drug that is metabolised by CYP2C9, such as metronidazole, fluconazole, NSAIDs, phenytoin or tolbutamide, that inhibit CYP2C9 metabolism, such as sulfaphenazole or sulfinpyrazone, or that induces CYP2C9, such as xenobiotics or alcohol, infampicin or barbiturates.
  • CYP2C9 such as metronidazole, fluconazole, NSAIDs, phenytoin or tolbutamide
  • CYP2C9 metabolism such as sulfaphenazole or sulfinpyrazone
  • CYP2C9 such as xenobiotics or alcohol, infampicin or barbiturates.
  • R-warfarin may be given to patients sensitive to racemate, such as the elderly and those with Werner's syndrome or any other ageing disorder.
  • suitable patients for treatment include those with renal and kidney diseases, impotence, osteoporosis or bone disease, vitamin deficiency, acne, dementia, Parkinsons disease, allergic disorders, infections, wounds, burns, epilepsy, gastrointestinal disorders, urological disorders, insomnia, pain, migraine, obesity, poor nutritional status, low weight, cardiovascular disease, addictive disorders, autoimmune disease, central nervous system disorder, neurological disease, endocrine disease, gynaecological disorders, pregnancy, cancer, skin disease, respiratory disease, orthopaedic conditions including hip fracture, or disorders of ears, nose and throat, patients who are immunocompromised, on contraception, being anaesthetised, post surgical or needing anticoagulation therapy, antiemetic therapy or treatment for vertigo who are on concurrent medication.
  • the present invention is particularly suitable for those people on warfarin who are likely to be in categories II, III, or IN, i.e. of relatively poor health.
  • the active agent may be made up into a suitable composition, and administered by means known to those skilled in the art.
  • suitable compositions and routes of administration include those that have already been used for racemic warfarin.
  • Suitable effective doses will depend on the usual factors, such as the severity of the condition being treated, the condition of the patient and other factors, but can readily be determined by the skilled man.
  • the daily dose of R-warfarin may be at least 0.1, 0.5, 1, 2, 5 mg or more, up to 10, 20, 50, 100 or 1000 mg.
  • the R-warfarin that is used in this invention is substantially free of S-warfarin.
  • it may be present in an enantiomeric excess of at least 90%, preferably at least 95%.
  • warfarin is used herein to define the compound itself or any salt, prodrug or other derivative which releases the active component on administration.
  • ILR International Normalized Ratio
  • Bleeding complications related to raised INR above the therapeutic range were classified as minor (requiring no additional testing, referral or outpatient visits), serious (requiring medical evaluation, blood transfusion of 2 units or fewer) or life- threatening (requiring surgical or angiographic intervention, transfusion of 3 or more units of blood, leading to irreversible sequelae), see Finn et al, supra. Bleeding episodes that occurred within the first four weeks of anticoagulation were classified as early, the rest as late.
  • CYP2C9 genotype distributions in low dose warfarin group compared with the clinic controls and the community controls are summarized in Table 1.
  • the odds ratio for individuals with a low warfarin dose requirement having one or more CYP2C9 variant alleles compared with the normal population was 6.21 (95% CI 2.48-15.6).
  • the odds ratio for a low dose warfarin patient possessing one variant allele only compared with the general population was 2.68 [95% CI 1.22-5.86] and two variant alleles 7.8 [95% CI 1.90- 32.1].
  • Genotype and allele frequencies were determined in the clinic controls to determine whether particular CYP2C9 genotypes might be associated with an increased risk of requiring anticoagulant treatment. There was no significant difference in CYP2C9 genotype frequencies between the clinic controls and the community control group. Age and sex were not confounders between the low dose group and clinic controls because the groups were not significantly different with respect to these factors. A further control group of 37 random anticoagulant clinic patients from another clinic in the same region studied had the same CYP2C9 genotype frequencies as the community control group (data not shown).
  • Duration of warfarin treatment was 0.2-17 yr. (median 2 yr.) for patients in the low dose group and 0.1-30 yr. (median 3.1 yr.) for patients in the clinic control group.
  • 7 minor, 5 serious and 6 life-threatening bleeding episodes occurred in 11 patients, including 1 patient where bleeding contributed to death. This compares with 6 minor, 5 serious and 2 life threatening bleeding episodes in 11 patients during 311.1 patient years of warfarin therapy in the clinic control group.
  • 6 minor and 1 major bleeding episodes occurred in 5 patients with in the first 4 weeks of induction of warfarin therapy. Each of these patient had one or more variant CYP2C9 alleles.
  • CYP2C9 genotype This study demonstrates a strong relationship between CYP2C9 genotype and warfarin sensitivity.
  • An individual requiring a low warfarin dose is 6 times more likely to be positive for one or more of the variant alleles associated with impaired S-warfarin metabolism (CYP2C9*2 and CYP2C9*3) compared with the general population.
  • CYP2C9 genotyping appears to have the potential to identify a sub-group of individuals who are poor metabolisers of warfarin, hence requiring very low dose.
  • the findings also indicate that significant proportion of these subjects have significant difficulties at the time of induction of warfarin therapy and have an increased risk of bleeding complications when compared with clinic controls.
  • Impaired metabolism of a low therapeutic index drug such as warfarin has significant clinical consequences. Difficulty in establishing optimal anticoagulation were experienced in 20 out of 36 (56%) patients in the low dose group with their peak LNR raising above the target range following a fixed dose regime. Eighteen of these patients carried one or more variant CYP2C9 alleles. Difficult induction resulted in delayed discharges, multiple visits to the clinics as well as additional investigations in an attempt to seek an explanation for warfarin sensitivity. A smaller warfarin dose requirement may be associated with greater variability of IN (Finn et al, supra) and this, coupled with a low therapeutic index inherent to warfarin, may lead to bleeding complications.

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

La R-warfarine est utile en tant qu'anticoagulant chez un patient présentant une sensibilité accrue à la warfarine racémique ou à la S-warfarine et permet de traiter et de prévenir des complications telles qu'hémorragies, associée à l'administration de la warfarine racémique.
PCT/GB2000/000154 1999-01-21 2000-01-21 Utilisation therapeutique de r-warfarine en tant qu'anticoagulant WO2000043003A1 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU30648/00A AU3064800A (en) 1999-01-21 2000-01-21 The therapeutic use of r-warfarin as anticoagulant

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
GBGB9901297.3A GB9901297D0 (en) 1999-01-21 1999-01-21 Diagnostic test and method
GB9901297.3 1999-01-21
GB9912184.0 1999-05-25
GBGB9912184.0A GB9912184D0 (en) 1999-05-25 1999-05-25 Therapeutic use

Publications (1)

Publication Number Publication Date
WO2000043003A1 true WO2000043003A1 (fr) 2000-07-27

Family

ID=26315012

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/GB2000/000154 WO2000043003A1 (fr) 1999-01-21 2000-01-21 Utilisation therapeutique de r-warfarine en tant qu'anticoagulant

Country Status (2)

Country Link
AU (1) AU3064800A (fr)
WO (1) WO2000043003A1 (fr)

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004003550A2 (fr) * 2002-06-28 2004-01-08 Xanthus Life Sciences, Inc. Individualisation de therapie par anticoagulants
WO2008082542A1 (fr) * 2006-12-19 2008-07-10 Institute For Therapeutic Research, Inc. Combinaison de vitamine k et d'un antagoniste de vitamine k, tel que l'isomère r de la warfarine, la phenprocoumone ou l'isomère r de la phenprocoumone, comme traitement anticoagulant
EP2189523A1 (fr) 2003-10-14 2010-05-26 Baxter International Inc. Polypeptide VKORC1 de recyclage de la vitamine k-epoxide, cible thérapeutique de la coumarine et de ses dérivés
US9441208B2 (en) 2003-09-23 2016-09-13 The University Of North Carolina At Chapel Hill Methods and compositions for producing vitamin K dependent proteins
US9631002B2 (en) 2010-12-21 2017-04-25 The University Of North Carolina At Chapel Hill Methods and compositions for producing active vitamin K-dependent proteins

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1995034679A2 (fr) * 1994-06-16 1995-12-21 The Government Of The United States Of America, Represented By The Secretary, Department Of Health And Human Services Metabolisme defectueux de medicaments
WO1997003062A1 (fr) * 1995-07-13 1997-01-30 The Du Pont Merck Pharmaceutical Company Nouvelle synthese asymetrique de warfarine r et s et ses analogues
WO1998040053A1 (fr) * 1997-03-11 1998-09-17 Darwin Discovery Limited Formes galeniques comprenant des parties separees d'enantiomeres r et s

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1995034679A2 (fr) * 1994-06-16 1995-12-21 The Government Of The United States Of America, Represented By The Secretary, Department Of Health And Human Services Metabolisme defectueux de medicaments
WO1997003062A1 (fr) * 1995-07-13 1997-01-30 The Du Pont Merck Pharmaceutical Company Nouvelle synthese asymetrique de warfarine r et s et ses analogues
WO1998040053A1 (fr) * 1997-03-11 1998-09-17 Darwin Discovery Limited Formes galeniques comprenant des parties separees d'enantiomeres r et s

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
AITHAL, GURUPRASAD P. (1) ET AL: "Relationship of polymorphisms in the cytochrome P450 CYP2C9 to warfarin dose requirement.", HEPATOLOGY, (1997) VOL. 26, NO. 4 PART 2, PP. 383A. MEETING INFO.: 48TH ANNUAL MEETING OF THE AMERICAN ASSOCIATION FOR THE STUDY OF LIVER DISEASES CHICAGO, ILLINOIS, USA NOVEMBER 7-11, 1997, XP000921130 *
O'REILLY R A: "The stereoselective interaction of warfarin and metronidazole in man.", NEW ENGLAND JOURNAL OF MEDICINE, (1976 AUG 12) 295 (7) 354-7., XP000921129 *
O'REILLY R.A.: "R(+) warfarin enantiomorph for stable oral anticoagulant therapy.", FEDERATION PROCEEDINGS, (1977) 36/3 (NO. 4269). CODEN: FEPRA7, XP000921192 *
STEWARD D J ET AL: "Genetic association between sensitivity to warfarin and expression of CYP2C9*3.", PHARMACOGENETICS, (1997 OCT) 7 (5) 361-7., XP000921131 *
YAMAZAKI H ET AL: "Human liver cytochrome P450 enzymes involved in the 7-hydroxylation of R- and S-warfarin enantiomers.", BIOCHEMICAL PHARMACOLOGY, (1997 DEC 1) 54 (11) 1195-203., XP000921132 *

Cited By (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004003550A2 (fr) * 2002-06-28 2004-01-08 Xanthus Life Sciences, Inc. Individualisation de therapie par anticoagulants
WO2004003550A3 (fr) * 2002-06-28 2004-11-04 Xanthus Life Sciences Inc Individualisation de therapie par anticoagulants
US9441208B2 (en) 2003-09-23 2016-09-13 The University Of North Carolina At Chapel Hill Methods and compositions for producing vitamin K dependent proteins
EP2189523A1 (fr) 2003-10-14 2010-05-26 Baxter International Inc. Polypeptide VKORC1 de recyclage de la vitamine k-epoxide, cible thérapeutique de la coumarine et de ses dérivés
EP2272951A1 (fr) 2003-10-14 2011-01-12 Baxter International Inc Polypeptide VKCORC1 de recyclage de la vitamine k-epoxide, cible thérapeutique de la coumarine et de ses dérivés
US9828588B2 (en) 2005-03-15 2017-11-28 The University Of North Carolina At Chapel Hill Methods and compositions for producing active vitamin K-dependent proteins
WO2008082542A1 (fr) * 2006-12-19 2008-07-10 Institute For Therapeutic Research, Inc. Combinaison de vitamine k et d'un antagoniste de vitamine k, tel que l'isomère r de la warfarine, la phenprocoumone ou l'isomère r de la phenprocoumone, comme traitement anticoagulant
US9631002B2 (en) 2010-12-21 2017-04-25 The University Of North Carolina At Chapel Hill Methods and compositions for producing active vitamin K-dependent proteins

Also Published As

Publication number Publication date
AU3064800A (en) 2000-08-07

Similar Documents

Publication Publication Date Title
AU2019203832B2 (en) Fenfluramine for use in the treatment of dravet syndrome
Haustein et al. Methotrexate in psoriasis: 26 years’ experience with low‐dose long‐term treatment
Sokolova et al. Hereditary persistence of hemoglobin F is protective against red cell sickling. A case report and brief review
CA2901410A1 (fr) Utilisation de levocetirizine et montelukast dans le traitement de blessure traumatique
CN115812000A (zh) 大麻二酚对脆性x综合征的治疗
Muroi et al. Magnesium and the inflammatory response: potential pathophysiological implications in the management of patients with aneurysmal subarachnoid hemorrhage?
Finch et al. Lithium augmentation in the treatment of refractory depression in old age
WO2000043003A1 (fr) Utilisation therapeutique de r-warfarine en tant qu'anticoagulant
Slaven et al. Spinal anesthesia for primary hip and knee arthroplasty: comparative rates of transient neurological symptoms and urinary retention using lidocaine, mepivacaine, and bupivacaine
Adjei et al. Amodiaquine-associated adverse effects after inadvertent overdose and after a standard therapeutic dose
Al-Mulla et al. Cancer in Sotos syndrome: report of a patient with acute myelocytic leukemia and review of the literature
Combe et al. Status dystonicus in children: early recognition and treatment prevent serious complications
Soualem et al. Oral manifestations and management of sickle cell disease: a literature review
WO2021161983A1 (fr) Nouveau médicament pour le traitement d'une maladie inflammatoire
Azizkhani et al. Analgesic effects of ketamine nebulizer vs. intravenous morphine in limb trauma patients in pre-hospital emergency setting; a randomized double-blinded clinical trial
Manandhar et al. Efficacy of intravenous Tramadol in prevention of catheter-related bladder discomfort in upper urinary tract surgery
Frenette et al. Thiopental‐Induced Neutropenia in Two Patients with Severe Head Trauma
Shirakami et al. Nocturnal episodic hypoxemia after ambulatory breast cancer surgery: Comparison of sevoflurane and propofol-fentanyl anesthesia
Leung et al. Pharmacotherapy during the end of life: caring for the actively dying patient
Saryazdi et al. A comparative study of the effect of low-dose epinephrine and ketamine on rapid-sequence endotracheal intubation by the priming dose method of cisatracurium in patients under general anesthesia
CN103203020B (zh) 他汀类药物在制备治疗慢性硬膜下血肿药物的用途
Koh et al. Dantrolene treatment in a patient with uncontrolled hyperthemia after general anesthesia: a case report of suspected malignant hyperthermia-A case report
Al-Najjar et al. Comparative study among gabapentin, midazolam and granisetron for prevention of postoperative nausea and vomiting after middle ear surgery
Rakotondrainibe et al. Comparison of oral and intravenous nefopam for fracture pain in Emergencies, Antananarivo
Richards Dexmedetomidine: pharmacology and use as a sedative agent

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): AE AL AM AT AU AZ BA BB BG BR BY CA CH CN CR CU CZ DE DK DM EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): GH GM KE LS MW SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

122 Ep: pct application non-entry in european phase
点击 这是indexloc提供的php浏览器服务，不要输入任何密码和下载